Difference between revisions of "Obinutuzumab (Gazyva)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Chemotherapeutic" to "") |
|||
| Line 17: | Line 17: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*11/1/2013: Granted FDA approval for use [[Chronic_lymphocytic_leukemia_(CLL)_and_Small_lymphocytic_lymphoma_(SLL)#Chlorambucil_.26_Obinutuzumab_.28GClb.29|in combination with chlorambucil]] for the treatment of patients with previously untreated [[Chronic lymphocytic leukemia | chronic lymphocytic leukemia (CLL)]]. | *11/1/2013: Granted FDA approval for use [[Chronic_lymphocytic_leukemia_(CLL)_and_Small_lymphocytic_lymphoma_(SLL)#Chlorambucil_.26_Obinutuzumab_.28GClb.29|in combination with chlorambucil]] for the treatment of patients with previously untreated [[Chronic lymphocytic leukemia | chronic lymphocytic leukemia (CLL)]]. | ||
| − | *2/26/2016: FDA approval expanded | + | *2/26/2016: FDA approval expanded for use [[Follicular_lymphoma#Bendamustine_.26_Obinutuzumab|in combination with bendamustine]] followed by [[Follicular_lymphoma#Obinutuzumab_monotherapy_3|obinutuzumab monotherapy]] for the treatment of patients with [[Follicular lymphoma|follicular lymphoma (FL)]] who relapsed after, or are refractory to, a [[Regimen_classes#Rituximab-containing_regimen|rituximab-containing regimen]]. |
| − | *11/16/2017: Granted regular FDA approval | + | *11/16/2017: Granted regular FDA approval in combination with chemotherapy, followed by obinutuzumab monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III, or IV [[Follicular lymphoma|follicular lymphoma (FL)]]. |
==Also known as== | ==Also known as== | ||
Revision as of 15:59, 3 February 2020
General information
Class/mechanism: Glyco-engineered anti-CD20 IgG1 type II monoclonal antibody. Engineered with a modified elbow hinge residue (valine instead of leucine at Kabat position 11) and a glyco-engineered Fc region, which is postulated to enhance its immunomodulatory effect.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.[1]
Diseases for which it is used
Patient drug information
No information available.
History of changes in FDA indication
- 11/1/2013: Granted FDA approval for use in combination with chlorambucil for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).
- 2/26/2016: FDA approval expanded for use in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.
- 11/16/2017: Granted regular FDA approval in combination with chemotherapy, followed by obinutuzumab monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III, or IV follicular lymphoma (FL).
Also known as
- Code names: GA101, R7159, RO5072759
- Generic name: afutuzumab
- Brand name: Gazyva